BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30587719)

  • 1. [Cancer Treatment-Induced Bone Loss(CTIBL)].
    Fukumoto S; Matsumoto T
    Gan To Kagaku Ryoho; 2018 Dec; 45(12):1685-1689. PubMed ID: 30587719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
    Takahashi S
    Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
    Brufsky AM
    Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab for cancer-related bone loss.
    Dell'Aquila E; Armento G; Iuliani M; Simonetti S; D'Onofrio L; Zeppola T; Madaudo C; Russano M; Citarella F; Ribelli G; Pantano F; Vincenzi B; Tonini G; Santini D
    Expert Opin Biol Ther; 2020 Nov; 20(11):1261-1274. PubMed ID: 32835531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of bone loss due to endocrine therapy during cancer treatment.
    Khan MI
    Osteoporos Int; 2023 Apr; 34(4):671-680. PubMed ID: 36656338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer.
    Takahashi S
    J Bone Miner Metab; 2023 May; 41(3):307-316. PubMed ID: 37036530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of bone health in patients with cancer: a survey of specialist nurses.
    Drudge-Coates L; van Muilekom E; de la Torre-Montero JC; Leonard K; van Oostwaard M; Niepel D; Jensen BT
    Support Care Cancer; 2020 Mar; 28(3):1151-1162. PubMed ID: 31203509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer treatment-induced bone loss in patients with breast or prostate cancer.
    Maxwell C; Viale PH
    Oncol Nurs Forum; 2005 May; 32(3):589-603. PubMed ID: 15897934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer treatment-induced bone loss. Treatment for breast cancer].
    Yamada K; Kohno N
    Clin Calcium; 2008 Apr; 18(4):507-17. PubMed ID: 18379033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy with bone-targeted agents.
    Wilson C; Coleman RE
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-treatment-induced bone loss, part 2.
    Michaud LB; Goodin S
    Am J Health Syst Pharm; 2006 Mar; 63(6):534-46. PubMed ID: 16522890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of bisphosphonates in the adjuvant setting for breast cancer.
    Reeder JG; Brufsky AM
    Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab and the current status of bone-modifying drugs in breast cancer.
    Lee BL; Higgins MJ; Goss PE
    Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic approaches for protecting bone health in patients with breast cancer.
    Lüftner D; Niepel D; Steger GG
    Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward new horizons: the future of bisphosphonate therapy.
    Lipton A
    Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving into the future: treatment of bone metastases and beyond.
    Hortobagyi GN
    Cancer Treat Rev; 2005; 31 Suppl 3():9-18. PubMed ID: 16249057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.